These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37080855)

  • 21. CyberKnife Stereotactic Ablative Radiotherapy as an Option of Treatment for Patients With Prostate Cancer Having Oligometastatic Lymph Nodes: Single-Center Study Outcome Evaluation.
    Napieralska A; Miszczyk L; Stąpór-Fudzińska M
    Technol Cancer Res Treat; 2016 Oct; 15(5):661-73. PubMed ID: 26208835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotactic Body Radiation Therapy (SBRT) Using CyberKnife in Oligometastatic Cancer Patients; Retrospective Evaluation, Single Institution Experience.
    Alsuhaibani A; Elashwah A; Alkafi A; Constantinescus C; ALzorkany F
    J Gastrointest Cancer; 2019 Dec; 50(4):879-887. PubMed ID: 30291546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereotactic body radiotherapy delivered with IMRT for oligometastatic regional lymph node metastases in hepatocellular carcinoma: a single-institutional study.
    Matoba M; Tsuchiya H; Kondo T; Ota K
    J Radiat Res; 2020 Sep; 61(5):776-783. PubMed ID: 32845298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salvage Stereotactic Body Radiotherapy for Patients With Prostate Cancer With Isolated Lymph Node Metastasis: A Single-Center Experience.
    Ponti E; Ingrosso G; Carosi A; Di Murro L; Lancia A; Pietrasanta F; Santoni R
    Clin Genitourin Cancer; 2015 Aug; 13(4):e279-e284. PubMed ID: 25604915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis.
    Onal C; Gultekin M; Oymak E; Guler OC; Yilmaz MT; Yuce Sari S; Akkus Yildirim B; Yildiz F
    Int J Gynecol Cancer; 2020 Jun; 30(6):865-872. PubMed ID: 32273293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial).
    Mercier C; Dirix P; Meijnders P; Vermeulen P; Van Laere S; Debois H; Huget P; Verellen D
    Radiat Oncol; 2018 Aug; 13(1):152. PubMed ID: 30126440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
    Shahi J; Poon I; Ung YC; Tsao M; Bjarnason GA; Malik NH; Zhang L; Louie AV; Cheung P
    Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):764-774. PubMed ID: 33115687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended-field radiotherapy for locally advanced cervical cancer.
    Thamronganantasakul K; Supakalin N; Kietpeerakool C; Pattanittum P; Lumbiganon P
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012301. PubMed ID: 30362204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
    Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases.
    Fumagalli I; Bibault JE; Dewas S; Kramar A; Mirabel X; Prevost B; Lacornerie T; Jerraya H; Lartigau E
    Radiat Oncol; 2012 Sep; 7():164. PubMed ID: 23014094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stereotactic body re-irradiation therapy for locally recurrent prostate cancer after external-beam radiation therapy: Initial report.
    Janoray G; Reynaud-Bougnoux A; Ruffier-Loubière A; Bernadou G; Pointreau Y; Calais G
    Cancer Radiother; 2016 Jun; 20(4):275-81. PubMed ID: 27342944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.
    Decaestecker K; De Meerleer G; Lambert B; Delrue L; Fonteyne V; Claeys T; De Vos F; Huysse W; Hautekiet A; Maes G; Ost P
    Radiat Oncol; 2014 Jun; 9():135. PubMed ID: 24920079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials.
    Pezzulla D; Macchia G; Cilla S; Buwenge M; Ferro M; Bonome P; Romano C; Zamagni A; Valentini V; Morganti AG; Deodato F
    Clin Exp Metastasis; 2021 Dec; 38(6):519-526. PubMed ID: 34651242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
    De Bleser E; Jereczek-Fossa BA; Pasquier D; Zilli T; Van As N; Siva S; Fodor A; Dirix P; Gomez-Iturriaga A; Trippa F; Detti B; Ingrosso G; Triggiani L; Bruni A; Alongi F; Reynders D; De Meerleer G; Surgo A; Loukili K; Miralbell R; Silva P; Chander S; Di Muzio NG; Maranzano E; Francolini G; Lancia A; Tree A; Deantoni CL; Ponti E; Marvaso G; Goetghebeur E; Ost P
    Eur Urol; 2019 Dec; 76(6):732-739. PubMed ID: 31331782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma.
    Feng XY; Li J; Li AM; Jing SH; Zhu XX; Wang Z
    World J Surg Oncol; 2022 Sep; 20(1):322. PubMed ID: 36171617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
    Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
    Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Outcomes of Stereotactic Body Radiotherapy for Patients With Stage I Small-Cell Lung Cancer: Analysis of a Subset of the Japanese Radiological Society Multi-Institutional SBRT Study Group Database.
    Shioyama Y; Onishi H; Takayama K; Matsuo Y; Takeda A; Yamashita H; Miyakawa A; Murakami N; Aoki M; Matsushita H; Matsumoto Y; Shibamoto Y;
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818783904. PubMed ID: 29983096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiotherapy in nodal oligorecurrent prostate cancer.
    Pinkawa M; Aebersold DM; Böhmer D; Flentje M; Ghadjar P; Schmidt-Hegemann NS; Höcht S; Hölscher T; Müller AC; Niehoff P; Sedlmayer F; Wolf F; Zamboglou C; Zips D; Wiegel T
    Strahlenther Onkol; 2021 Jul; 197(7):575-580. PubMed ID: 33914101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.